EMA Prepares for EudraVigilance Adverse Event Reporting Overhaul

Drug Industry Daily
A A
The European Medicines Agency’s EudraVigilance system for monitoring adverse events is undergoing an overhaul to comply with new postmarketing clinical trials legislation, and regulators are readying drugmakers and national authorities for a new plan.

To View This Article:

Login

Subscribe To Drug Industry Daily